Interatrial shunting as a treatment for heart failure: Where do we stand?
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 26, 2024 Category: Cardiology Authors: Thomas M. Gorter,
Elke S. Hoendermis,
Dirk J. van Veldhuisen Tags: Invited Editorial Source Type: research
Baroreceptors as a target of device ‐based neuromodulation in heart failure: Long‐term outcomes
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 25, 2024 Category: Cardiology Authors: Guido Grassi,
Raffaella Dell'Oro,
Fosca Quarti ‐Trevano Tags: Invited Editorial Source Type: research
Is it NICE to measure natriuretic peptides after a hospitalization for heart failure?
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 24, 2024 Category: Cardiology Authors: Matteo Pagnesi,
Marianna Adamo,
Marco Metra Tags: Invited Editorial Source Type: research
Follow the EMPULSE: In ‐hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 24, 2024 Category: Cardiology Authors: Tann Lien,
Kishan Srikanth,
Andrew P. Ambrosy Tags: Invited Editorial Source Type: research
Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE ‐HF2 trial design
ConclusionsThe RESHAPE-HF2 trial will provide sound evidence on the MitraClip device and its effects in HF patients with FMR. The recruitment was recently completed with 506 randomized patients. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 24, 2024 Category: Cardiology Authors: Stefan D. Anker,
Tim Friede,
Ralph Stephan von Bardeleben,
Javed Butler,
Kaneez Fatima,
Monika Diek,
Jutta Heinrich,
Gerd Hasenfu ß,
Wolfgang Schillinger,
Piotr Ponikowski Tags: Study Design Source Type: research
Role of stiff atrium in elucidating diastolic dysfunction in Fontan circulation. Letter regarding the article ‘Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology’
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 20, 2024 Category: Cardiology Authors: Makoto Takei Tags: Letter to Editor Source Type: research
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function
Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping ...
Source: European Journal of Heart Failure - April 19, 2024 Category: Cardiology Authors: Pietro Ameri,
Valentina Mercurio,
Piero Pollesello,
Markus S. Anker,
Johannes Backs,
Antoni Bayes ‐Genis,
Barry A. Borlaug,
Daniel Burkhoff,
Sergio Caravita,
Stephen Y. Chan,
Frances de Man,
George Giannakoulas,
Aránzazu González,
Marco G Tags: Position Paper Source Type: research
Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium
The interplay of MR and HFpEF: understanding increased pulmonary pressures and strategies for management. HFpEF, heart failure with preserved ejection fraction; MR, mitral valve regurgitation. AbstractMitral regurgitation (MR) is highly prevalent among patients with heart failure and preserved ejection fraction (HFpEF). Despite this combination being closely associated with unfavourable outcomes, it remains relatively understudied. This is partly due to the inherent heterogeneity of patients with HFpEF. To address this gap, dissecting HFpEF into mechanism-based phenotypes may offer a promising avenue for advancing our comp...
Source: European Journal of Heart Failure - April 18, 2024 Category: Cardiology Authors: Sebastiaan Dhont,
Gitte van den Acker,
Tim van Loon,
Frederik H. Verbrugge,
Jan Verwerft,
S ébastien Deferm,
Timothy W. Churchill,
Wilfried Mullens,
Joost Lumens,
Philippe B. Bertrand Tags: Review Article Source Type: research
Long ‐term efficacy and safety of tailored immunosuppressive therapy in immune‐mediated biopsy‐proven myocarditis: A propensity‐weighted study
ConclusionsProlonged tailored IS is effective and safe in BP immune-mediated myocarditis irrespective of histology and clinical presentation. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 17, 2024 Category: Cardiology Authors: Alida Linda Patrizia Caforio,
Andrea Silvio Giordani,
Anna Baritussio,
Davide Marcolongo,
Cristina Vicenzetto,
Giuseppe Tarantini,
Massimo Napodano,
Giuseppe Toscano,
Dario Gregori,
Gloria Brigiari,
Patrizia Bartolotta,
Elisa Carturan,
Monica Tags: Research Article Source Type: research
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 17, 2024 Category: Cardiology Authors: Rahul Aggarwal,
Deepak L. Bhatt,
Michael Szarek,
Lawrence A. Leiter,
Christopher P. Cannon,
Renato D. Lopes,
Michael J Davies,
Phillip Banks,
Bertram Pitt,
Ph. Gabriel Steg Tags: Research Letter Source Type: research
Reporting quality of heart failure randomized controlled trials 2000 –2020: Temporal trends in adherence to CONSORT criteria
ConclusionThe quality of reporting in HF RCTs, as measured by CONSORT adherence, has improved over time but remains suboptimal. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 17, 2024 Category: Cardiology Authors: Mohamed B. Jalloh,
Veronica A. Bot,
Cristiana Z. Borjaille,
Lehana Thabane,
Guowei Li,
Javed Butler,
Faiez Zannad,
Christopher B. Granger,
Harriette G.C. Van Spall Tags: Research Article Source Type: research
The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium –glucose cotransporter 2 inhibitors?
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 16, 2024 Category: Cardiology Authors: Aldostefano Porcari,
Marianna Fontana Tags: Invited Editorial Source Type: research
Serum metabolomics improves risk stratification for incident heart failure
ConclusionSerum metabolomics improves incident HF risk prediction over PCP-HF. Scores based on age, sex and metabolomics exhibit similar predictive power to clinically-based models, potentially offering a cost-effective, standardizable, and scalable single-domain alternative. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 16, 2024 Category: Cardiology Authors: Rafael R. Oexner,
Hyunchan Ahn,
Konstantinos Theofilatos,
Ravi A. Shah,
Robin Schmitt,
Philip Chowienczyk,
Anna Zoccarato,
Ajay M. Shah Tags: Research Article Source Type: research
Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC
Sodium and fluid restriction has traditionally been advocated in patients with heart failure (HF) due to their sodium and water avid state. However, most evidence regarding the altered sodium handling, fluid homeostasis and congestion-related signs and symptoms in patients with HF originates from untreated patient cohorts and physiological investigations. Recent data challenge the beneficial role of dietary sodium and fluid restriction in HF. Consequently, the European Society of Cardiology HF guidelines have gradually downgraded these recommendations over time, now advising for the limitation of salt intake to no more tha...
Source: European Journal of Heart Failure - April 13, 2024 Category: Cardiology Authors: Wilfried Mullens,
Kevin Damman,
Sebastiaan Dhont,
Debasish Banerjee,
Antoni Bayes ‐Genis,
Antonio Cannata,
Ovidiu Chioncel,
Maja Cikes,
Justin Ezekowitz,
Andreas J. Flammer,
Pieter Martens,
Alexandre Mebazaa,
Robert J. Mentz,
Òscar Miró, Tags: Position Paper Source Type: research
Cause ‐specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry
ConclusionCardiovascular death was more common than non-CV death across all EF categories although the risk of non-CV death within 5 years was higher with increasing EF. IHD and cancer were the most common causes of CV and non-CV deaths, respectively, regardless of EF category. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 12, 2024 Category: Cardiology Authors: Camilla Settergren,
Lina Benson,
Angiza Shahim,
Ulf Dahlstr öm,
Tonje Thorvaldsen,
Gianluigi Savarese,
Lars H. Lund,
Bahira Shahim Tags: Research Article Source Type: research
